ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: Bendamustine, CCR4 inhibitors [146], ALK inhibitors [147], DNA methyltransferase (DNMT) inhibitors [8], CD138 monoclonal antibody, CD52 monoclonal antibody [148], antiviral drugs, immunomodulators, EZH2 and EZH1 dual inhibitors [149], are drugs that have achieved very encouraging clinical trials in relapsed and refractory PTCL.